In-Vitro Activities of Terbinafine, Itraconazole and Amphotericin B Against Aspergillus and Cladosporium species

References

• Hospenthal OR, Kwon-Chung KJ, Bennett JE. Concentrations of airborne Aspergillus compared to the inci-dence of invazive aspergillosis: lack of correlation. Med Mycol 1998; 36: 165–168.
   PubMed Web of Science ®Google Scholar
• Leenders ACAP, van Belkum A, Behrendt M, Luijendijk AD, Verbrugh HA. Density and molecular epidemiology of Aspergillus in air and relationship to outbreaks of Aspergillus infection. J Clin Microbiol 1999; 37: 1752–1757.
   PubMed Web of Science ®Google Scholar
• VandenBergh M, Verveij P, Voss A. Epidemiology of nosocomial fungal infections: invazive aspergillosis and the environment. Diagn Microbiol Infect Dis 1999; 34: 221–227.
   PubMed Web of Science ®Google Scholar
• Yticel A, Kantarcioglu S. A microbiological study in Topkapi Palace Library (Istanbul), 3rd International Conference on Biodeterioration of Cultural Properties, 4-7 July 1995, Bangkok, Thailand, Proceedings, 1995: 400-413.
   Google Scholar
• Bodey G, BueltmanB B, Duguid W, et al. Fungal infec-tions in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992: 11: 99–109.
   PubMed Web of Science ®Google Scholar
• Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invazive fungal infections at a university hospital. J Infect 1996; 33: 23–32.
   PubMed Web of Science ®Google Scholar
• Kaiser L, Huguenin T, Lew PD, Chapuis B, Pittet D. Invazive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine 1998; 77: 188–194.
   Google Scholar
• Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 2: 310–350.
   Google Scholar
• de Hoog GS, Guarro J, Gene JL, Figueras MJ. Atlas of Clinical Fungi. 2nd ed. Centraalbureau voor Schimmelcultures, Universitat Rovira i Virgilli, Utrecht/Reus, 2000.
   Google Scholar
• Matsumoto T, Ajello L, Matsuda T, Szaniszlo PJ, Walsh TJ. Developments in hyalohyphomycosis and phaeohyphomy-cosis. J Med Vet Mycol 1994; 32 (Suppl 1): 329–349.
   PubMedGoogle Scholar
• Roberts DT. Terbinafine (Lamisil) in the treatment of onychomycosis. J Dermatol Treatment 1998; 9: 53–58.
   Google Scholar
• Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997; 8: 275–287.
   Google Scholar
• Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol 2000; 38: 155–159.
   PubMed Web of Science ®Google Scholar
• Moore CB, Walls CM, Denning DW. In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Antimicrob Agents Chemother 2001; 45: 1882–1885.
   PubMed Web of Science ®Google Scholar
• McGinnis MR, Pasarell L. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med Mycol 1998; 36: 243–246.
   PubMed Web of Science ®Google Scholar
• Perez A. Terbinafine: broad new spectrum of indica-tions in several subcutaneous and systemic and parasitic dis-eases. Mycoses 1999; 42 (Suppl: 2): 11-114.
   Google Scholar
• Schiraldi GF, Lo Cicero S, Colombo MD, Rossato D, Ferrarese M, Soresi E. Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Br J Dermatol 1996; 134 (Suppl 46): 25–29.
   PubMed Web of Science ®Google Scholar
• Schiraldi G F, Colombo MD, Harari S, et al. Terbinafine in the treatment of non-immunocompromised compassionate cases of bronchopulmonary aspergillosis. Mycoses 1996; 39: 5–12.
   PubMed Web of Science ®Google Scholar
• Vieira MR, Milheiro A, Pacheco FA. Phaeohyphomycosis due to Cladosporium cladosporioides. Med Mycol 2001; 39: 135–137.
   PubMed Web of Science ®Google Scholar
• Ellis DH. The potential for terbinafine in non-dermato-phyte fungal infections with or without skin involvement. J Dermatol Treatment 1998; 9 (Suppl 1): S35–S38.
   Google Scholar
• Raper KB, Fennell DI. Aspergillus. The Williams and Wilkins Company, Baltimore, Md. 1965.
   Google Scholar
• Samson RA, Hoekstra ES, Frisvad FC, Filtenborg O. Introduction to Food-borne Fungi. 4th ed. Centraalbureau voor Schimmelcultures, Baarn. 1995.
   Google Scholar
• Ellis MB. Dematiaceous Hyphomycetes. Commonwealth Mycological Institute. Kew, Surrey, England. 1993.
   Google Scholar
• Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314–319.
   PubMed Web of Science ®Google Scholar
• Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Can dida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 1998; 42: 1057–1061.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi; Proposed Standard. Document M38-P. National Committee for Clinical Laboratory Standards. Wayne, Pa. 1998: 7.
   Google Scholar
• Espinel-Ingroff A, Bartlett M, Chaturverdi V, et al. Optimal susceptibility testing conditions for detecting of azole resistance in Aspergillus spp.: NCCLS Collaborative evalua-tion. Antimicrob Agents Chemother 2001; 45: 1828-1835.
   Google Scholar
• Ryder N S, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001; 39: 91–95.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against oppor-tunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954–958.
   PubMed Web of Science ®Google Scholar
• Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus infection. J Antimicrob Chemother 1997; 40: 401–414.
   PubMed Web of Science ®Google Scholar
• Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364–1368.
   PubMed Web of Science ®Google Scholar
• Guarro J, Llop C, Aguilar C, Pujol I. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of fila-mentous fungi. Antimicrob Agents Chemother 1997; 41: 2760–2762.
   PubMed Web of Science ®Google Scholar
• Ryder N S, Leitner I. In vitro activity of terbinafine (Lamisil): An update. J Dermatol Treat 1998; 9 (Suppl 1): S23–S28.
   Google Scholar
• Esterre P, Inzan CK, Ratsioharana M, et al. A multi-centre trial of terbinafine in patients with chromoblastomyco-sis. Effect on clinical and biological criteria. J Dermatol Treat 1998; 9 (Suppl 1): S29–S34.
   Google Scholar
• Ankan S, Lozano-Chiu M, Paetznick W, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itra-conazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37: 3946–3951.
   PubMed Web of Science ®Google Scholar
• Hennequin C, Benailly N, Silly C, et al. In vitro sus-ceptibilities to amphotericin B, itraconazole, and miconazole of filamentous fungi isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 1997; 41: 2064–2066.
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal sus-ceptibility testing: Practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643–658.
   PubMed Web of Science ®Google Scholar
• Llopp C, Pujol I, Aguilar C, Sala J, Riba D, Guarro J. Comparison of three methods of determining MICs for fila-mentous fungi using different end point criteria and incubation periods. Antimicrob Agents Chemother 2000; 44: 239–242.
   PubMed Web of Science ®Google Scholar